As such, NF-κB signaling intermediates are attractive therapeutic targets for airway diseases such as asthma, as the underlying inflammation is independent of stimuli [34] and is mediated at least in part by NF-κB mediated signaling in bronchial fibroblasts (Figure 1). Here, NFKB1 is linked to asthma.